Sign in Subscribe
Antiarthritic agents

Regulatory B Cells Play Pivotal Role in Immune Modulation of Rheumatoid Arthritis

Strategic Insights

— 1 min read

New research on rheumatoid arthritis (RA) has shed light on the vital role of regulatory B cells (Bregs) in the immune modulation of the disease. A study conducted by Jinan University Shenzhen People's Hospital found that the levels of CD19+CD24hiCD38hi Bregs in peripheral blood were significantly lower in RA patients compared to healthy controls, suggesting a potential association between Breg levels and the pathogenesis and inflammatory activity of RA.

Key Takeaways:

  • The study enrolled 90 patients with newly diagnosed RA and 32 healthy controls, and found that the levels of CD19+CD24hiCD38hi Bregs in RA patients were 89.63% of those in healthy controls.
  • No significant differences in Breg levels were observed among patients with different disease activities, but there was a positive correlation between CD19+CD24hiCD38hi Breg levels and morning stiffness duration.
  • A follow-up study of 26 RA patients showed a significant increase in CD19+CD24hiCD38hi Breg levels after six months of treatment, accompanied by a decrease in disease activity scores.
  • The research suggests that CD19+CD24hiCD38hi Bregs may serve as potential biomarkers for evaluating disease activity and treatment efficacy in RA.
  • The study highlights the need for further research to explore the underlying biological mechanisms and clinical significance of Bregs in RA.

Statistics:

  • 90 patients with newly diagnosed RA were enrolled in the study.
  • 32 healthy controls were enrolled in the study.
  • The levels of CD19+CD24hiCD38hi Bregs in RA patients were 89.63% of those in healthy controls.
  • No significant differences in Breg levels were observed among patients with different disease activities.
  • The follow-up study included 26 RA patients, and showed a significant increase in CD19+CD24hiCD38hi Breg levels after six months of treatment.
  • The disease activity scores decreased by an average of 30% in the follow-up study.

Sources:

  • Jinan University Shenzhen People's Hospital
  • Advances in Rheumatology (https://advancesinrheumatology.biomedcentral.com/)
  • BMC (publisher of Advances in Rheumatology)
  • Lijun Chen, Department of Rheumatology and Immunology, Second Clinical Medical College, Jinan University (Shenzhen People's Hospital)
  • Jianjun Xu, Baodong Sun, Xiaoping Hong, Dongzhou Liu, Heng Li (authors of the research)

Read more